Articles by Zachary Bessette
Tala/enza demonstrated improvement in OS compared with enza alone as 1L treatment in patients with mCRPC.
Increased levels of circulating KIM-1 are associated with worse outcomes for patients receiving nivo/ipi or sunitinib alone.
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
The final results of the CONTACT-02 trial show favorable, but not statistically significant, benefit for cabo/atezo in mCRPC.
Perioperative durvalumab with NAC offers “meaningful improvement” in EFS and OS for patients with cisplatin-ineligible ...
Results of SunRISe-1 provide support for TAR-200 monotherapy in patients with BCG-unresponsive high-risk NMIBC.
EV/pembro may offer first-line PFS and OS benefit in patients with la/mUC, regardless of Nectin-4 expression.
A phase 2 study highlights the “encouraging” antitumor activity from futibatinib plus pembrolizumab for patients with ...
The addition of nivo to trimodality therapy may improve RFS in patients with non-metastatic muscle-invasive bladder cancer.
The FDA has accepted an NDA for TLX007-CDx, a cold kit for the preparation of PSMA-PET imaging for prostate cancer.
A phase 3 trial offers the first randomized evidence of the benefit of PSMA tandem therapy in patients with mCRPC.
New research provides evidence of 18F-rhPSMA-7 leading to more favorable disease outcomes for patients with BCR after RP.
Dr. Mark David Linch presented the results of NEPTUNES: a multicenter, 2-cohot, biomarker-selected, phase 2 trial.
Results from the CHAARTED2 trial was presented by Dr. Kyriakopoulos of the University of Wisconsin Carbone Cancer Center.
Neoadjuvant SG shows promising clinical activity in patients with MIBC and may help avoid radical cystectomy.
A recent trial provides the first evidence of efficacy from ICIs in PSCC with a manageable safety profile.
An update on clinical efficacy and an exploratory biomarker analysis from the NABUCCO trial for patients with stage III UC.
Patients with RCC who experience disease recurrence after adjuvant IO benefit from subsequent systemic therapies.
The SWENOTECA cancer care program sought to evaluate survival, toxicity in patients treated with HDCT from 2011 through 2021.
Researchers attempted to confirm whether treatment suspension for EMBARK patients may lead to improvements in HRQOL.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.